TY - JOUR AU - Bianchi, G. AU - Anderson, K. C. PY - 2014 DA - 2014// TI - Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back JO - CA Cancer J Clin VL - 64 UR - https://doi.org/10.3322/caac.21252 DO - 10.3322/caac.21252 ID - Bianchi2014 ER - TY - JOUR AU - Rollig, C. AU - Knop, S. AU - Bornhauser, M. PY - 2015 DA - 2015// TI - Multiple myeloma JO - Lancet VL - 385 UR - https://doi.org/10.1016/S0140-6736(14)60493-1 DO - 10.1016/S0140-6736(14)60493-1 ID - Rollig2015 ER - TY - JOUR AU - Dimopoulos, M. A. AU - Terpos, E. PY - 2010 DA - 2010// TI - Multiple myeloma JO - Ann Oncol. VL - 21 UR - https://doi.org/10.1093/annonc/mdq370 DO - 10.1093/annonc/mdq370 ID - Dimopoulos2010 ER - TY - JOUR AU - Turesson, I. AU - Bjorkholm, M. AU - Blimark, C. H. AU - Kristinsson, S. AU - Velez, R. AU - Landgren, O. PY - 2018 DA - 2018// TI - Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival JO - Eur J Haematol VL - 101 UR - https://doi.org/10.1111/ejh.13083 DO - 10.1111/ejh.13083 ID - Turesson2018 ER - TY - JOUR AU - Abramson, H. N. PY - 2018 DA - 2018// TI - The multiple myeloma drug pipeline-2018: a review of small molecules and their therapeutic targets JO - Clin Lymphoma Myeloma Leuk VL - 18 UR - https://doi.org/10.1016/j.clml.2018.06.015 DO - 10.1016/j.clml.2018.06.015 ID - Abramson2018 ER - TY - JOUR AU - Roex, G. AU - Feys, T. AU - Beguin, Y. AU - Kerre, T. AU - Poiré, X. AU - Lewalle, P. PY - 2020 DA - 2020// TI - Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: an update of the pivotal clinical trial data JO - Pharmaceutics VL - 12 UR - https://doi.org/10.3390/pharmaceutics12020194 DO - 10.3390/pharmaceutics12020194 ID - Roex2020 ER - TY - JOUR AU - Wu, C. AU - Zhang, L. AU - Brockman, Q. R. AU - Zhan, F. AU - Chen, L. PY - 2019 DA - 2019// TI - Chimeric antigen receptor T cell therapies for multiple myeloma JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0823-5 DO - 10.1186/s13045-019-0823-5 ID - Wu2019 ER - TY - JOUR AU - Cohen, A. D. PY - 2018 DA - 2018// TI - CAR-T cells and other cellular therapies for multiple myeloma: 2018 update JO - Am Soc Clin Oncol Educ Book VL - 38 UR - https://doi.org/10.1200/EDBK_200889 DO - 10.1200/EDBK_200889 ID - Cohen2018 ER - TY - JOUR AU - Hartmann, J. AU - Schüßler-Lenz, M. AU - Bondanza, A. AU - Buchholz, C. J. PY - 2017 DA - 2017// TI - Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts JO - EMBO Mol Med VL - 9 UR - https://doi.org/10.15252/emmm.201607485 DO - 10.15252/emmm.201607485 ID - Hartmann2017 ER - TY - JOUR AU - Danhof, S. AU - Hudecek, M. AU - Smith, E. L. PY - 2018 DA - 2018// TI - CARs and other T cell therapies for MM: the clinical experience JO - Best Pract Res Clin Haematol VL - 31 UR - https://doi.org/10.1016/j.beha.2018.03.002 DO - 10.1016/j.beha.2018.03.002 ID - Danhof2018 ER - TY - JOUR AU - Timmers, M. AU - Roex, G. AU - Wang, Y. AU - Campillo-Davo, D. AU - Tendeloo, V. F. I. AU - Chu, Y. PY - 2019 DA - 2019// TI - Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen JO - Front Immunol VL - 10 UR - https://doi.org/10.3389/fimmu.2019.01613 DO - 10.3389/fimmu.2019.01613 ID - Timmers2019 ER - TY - JOUR AU - Yu, B. AU - Jiang, T. AU - Liu, D. PY - 2020 DA - 2020// TI - BCMA-targeted immunotherapy for multiple myeloma JO - J Hematol Oncol VL - 13 UR - https://doi.org/10.1186/s13045-020-00962-7 DO - 10.1186/s13045-020-00962-7 ID - Yu2020 ER - TY - JOUR AU - Grupp, S. A. AU - Kalos, M. AU - Barrett, D. AU - Aplenc, R. AU - Porter, D. L. AU - Rheingold, S. R. PY - 2013 DA - 2013// TI - Chimeric antigen receptor-modified T cells for acute lymphoid leukemia JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1215134 DO - 10.1056/NEJMoa1215134 ID - Grupp2013 ER - TY - JOUR AU - Maude, S. L. AU - Frey, N. AU - Shaw, P. A. AU - Aplenc, R. AU - Barrett, D. M. AU - Bunin, N. J. PY - 2014 DA - 2014// TI - Chimeric antigen receptor T cells for sustained remissions in leukemia JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1407222 DO - 10.1056/NEJMoa1407222 ID - Maude2014 ER - TY - JOUR AU - Wang, Y. AU - Luo, F. AU - Yang, J. AU - Zhao, C. AU - Chu, Y. PY - 2017 DA - 2017// TI - New chimeric antigen receptor design for solid tumors JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.01934 DO - 10.3389/fimmu.2017.01934 ID - Wang2017 ER - TY - JOUR AU - D’Agostino, M. AU - Raje, N. PY - 2020 DA - 2020// TI - Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? JO - Leukemia VL - 34 UR - https://doi.org/10.1038/s41375-019-0669-4 DO - 10.1038/s41375-019-0669-4 ID - D’Agostino2020 ER - TY - JOUR AU - Liu, D. AU - Zhao, J. PY - 2018 DA - 2018// TI - Cytokine release syndrome: grading, modeling, and new therapy JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0653-x DO - 10.1186/s13045-018-0653-x ID - Liu2018 ER - TY - JOUR AU - Gagelmann, N. AU - Ayuk, F. AU - Atanackovic, D. AU - Kröger, N. PY - 2020 DA - 2020// TI - B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis JO - Eur J Haematol VL - 104 UR - https://doi.org/10.1111/ejh.13380 DO - 10.1111/ejh.13380 ID - Gagelmann2020 ER - TY - JOUR AU - Garfall, A. L. AU - Maus, M. V. AU - Hwang, W. T. AU - Lacey, S. F. AU - Mahnke, Y. D. AU - Melenhorst, J. J. PY - 2015 DA - 2015// TI - Chimeric antigen receptor T cells against CD19 for multiple myeloma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504542 DO - 10.1056/NEJMoa1504542 ID - Garfall2015 ER - TY - JOUR AU - Cohen, A. D. AU - Garfall, A. L. AU - Stadtmauer, E. A. AU - Melenhorst, J. J. AU - Lacey, S. F. AU - Lancaster, E. PY - 2019 DA - 2019// TI - B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma JO - J Clin Invest VL - 129 UR - https://doi.org/10.1172/JCI126397 DO - 10.1172/JCI126397 ID - Cohen2019 ER - TY - JOUR AU - Cohen, A. D. AU - Melenhorst, J. J. AU - Garfall, A. L. AU - Lacey, S. F. AU - Davis, M. AU - Vogl, D. T. PY - 2018 DA - 2018// TI - Predictors of T cell expansion and clinical responses following B-cell maturation antigen-specific chimeric antigen receptor T cell therapy (CART-BCMA) for relapsed/refractory multiple myeloma (MM) JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-119665 DO - 10.1182/blood-2018-99-119665 ID - Cohen2018 ER - TY - JOUR AU - Han, L. AU - Gao, Q. AU - Zhou, K. AU - Zhou, J. AU - Fang, B. AU - Zhang, J. PY - 2019 DA - 2019// TI - The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2535 DO - 10.1200/JCO.2019.37.15_suppl.2535 ID - Han2019 ER - TY - JOUR AU - Kumar, S. AU - Paiva, B. AU - Anderson, K. C. AU - Durie, B. AU - Landgren, O. AU - Moreau, P. PY - 2016 DA - 2016// TI - International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30206-6 DO - 10.1016/S1470-2045(16)30206-6 ID - Kumar2016 ER - TY - JOUR AU - Raje, N. AU - Berdeja, J. AU - Lin, Y. AU - Siegel, D. AU - Jagannath, S. AU - Madduri, D. PY - 2019 DA - 2019// TI - Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1817226 DO - 10.1056/NEJMoa1817226 ID - Raje2019 ER - TY - JOUR AU - Brudno, J. N. AU - Maric, I. AU - Hartman, S. D. AU - Rose, J. J. AU - Wang, M. AU - Lam, N. PY - 2018 DA - 2018// TI - T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.77.8084 DO - 10.1200/JCO.2018.77.8084 ID - Brudno2018 ER - TY - JOUR AU - Mailankody, S. AU - Ghosh, A. AU - Staehr, M. AU - Purdon, T. J. AU - Roshal, M. AU - Halton, E. PY - 2018 DA - 2018// TI - Clinical responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a phase I clinical trial JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-119717 DO - 10.1182/blood-2018-99-119717 ID - Mailankody2018 ER - TY - JOUR AU - Yan, Z. AU - Cao, J. AU - Cheng, H. AU - Qiao, J. AU - Zhang, H. AU - Wang, Y. PY - 2019 DA - 2019// TI - A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial JO - Lancet Haematol VL - 6 UR - https://doi.org/10.1016/S2352-3026(19)30115-2 DO - 10.1016/S2352-3026(19)30115-2 ID - Yan2019 ER - TY - JOUR AU - Raje, N. AU - Berdeja, J. AU - Lin, Y. AU - Munshi, N. AU - Siegel, D. S. D. AU - Liedtke, M. PY - 2018 DA - 2018// TI - bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: updated results from a multicenter phase I study JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.8007 DO - 10.1200/JCO.2018.36.15_suppl.8007 ID - Raje2018 ER - TY - JOUR AU - Berdeja, J. G. AU - Alsina, M. AU - Shah, N. D. AU - Siegel, D. S. AU - Jagannath, S. AU - Madduri, D. PY - 2019 DA - 2019// TI - Updated results from an ongoing phase 1 clinical study of bb21217 anti-bcma CAR-T-cell therapy JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-126660 DO - 10.1182/blood-2019-126660 ID - Berdeja2019 ER - TY - JOUR AU - Xu, J. AU - Wang, Q. AU - Xu, H. AU - Gu, C. AU - Jiang, L. AU - Wang, J. PY - 2018 DA - 2018// TI - Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0672-7 DO - 10.1186/s13045-018-0672-7 ID - Xu2018 ER - TY - JOUR AU - Li, C. AU - Wang, Q. AU - Zhu, H. AU - Mao, X. AU - Wang, Y. AU - Zhang, Y. PY - 2018 DA - 2018// TI - T cells expressing anti B-cell maturation antigen chimeric antigen receptors for plasma cell malignancies JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-116898 DO - 10.1182/blood-2018-99-116898 ID - Li2018 ER - TY - JOUR AU - Ali, S. A. AU - Shi, V. AU - Maric, I. AU - Wang, M. AU - Stroncek, D. F. AU - Rose, J. J. PY - 2016 DA - 2016// TI - T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma JO - Blood VL - 128 UR - https://doi.org/10.1182/blood-2016-04-711903 DO - 10.1182/blood-2016-04-711903 ID - Ali2016 ER - TY - JOUR AU - Li, C. AU - Mei, H. AU - Hu, Y. AU - Guo, T. AU - Liu, L. AU - Jiang, H. PY - 2019 DA - 2019// TI - A bispecific CAR-T cell therapy targeting bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-130340 DO - 10.1182/blood-2019-130340 ID - Li2019 ER - TY - JOUR AU - Jie, J. AU - Hao, S. AU - Jiang, S. AU - Li, Z. AU - Yang, M. AU - Zhang, W. PY - 2019 DA - 2019// TI - Phase 1 trial of the safety and efficacy of fully human anti-bcma CAR T cells in relapsed/refractory multiple myeloma JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-126104 DO - 10.1182/blood-2019-126104 ID - Jie2019 ER - TY - JOUR AU - Jiang, S. AU - Jin, J. AU - Hao, S. AU - Yang, M. AU - Chen, L. AU - Ruan, H. PY - 2018 DA - 2018// TI - Low dose of human scFv-derived BCMA-targeted CAR-T cells achieved fast response and high complete remission in patients with relapsed/refractory multiple myeloma JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-113220 DO - 10.1182/blood-2018-99-113220 ID - Jiang2018 ER - TY - JOUR AU - Mailankody, S. AU - Htut, M. AU - Lee, K. P. AU - Bensinger, W. AU - Devries, T. AU - Piasecki, J. PY - 2018 DA - 2018// TI - JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE) JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-113548 DO - 10.1182/blood-2018-99-113548 ID - Mailankody2018 ER - TY - JOUR AU - Yao, X. AU - Zhu, S. AU - Huang, J. AU - Qu, X. AU - Zhu, J. AU - Wei, Y. PY - 2019 DA - 2019// TI - Developing a novel anti-bcma CAR-T for relapsed or refractory multiple myeloma JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-125372 DO - 10.1182/blood-2019-125372 ID - Yao2019 ER - TY - JOUR AU - Li, C. AU - Wang, J. AU - Wang, D. AU - Hu, G. AU - Yang, Y. AU - Zhou, X. PY - 2019 DA - 2019// TI - Efficacy and safety of fully human BCMA targeting CAR T cell therapy in relapsed/refractory multiple myeloma JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-128468 DO - 10.1182/blood-2019-128468 ID - Li2019 ER - TY - JOUR AU - Garfall, A. L. AU - Cohen, A. D. AU - Lacey, S. F. AU - Tian, L. AU - Hwang, W. -. T. AU - Vogl, D. T. PY - 2019 DA - 2019// TI - Combination anti-BCMA and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-131515 DO - 10.1182/blood-2019-131515 ID - Garfall2019 ER - TY - JOUR AU - Green, D. J. AU - Pont, M. AU - Sather, B. D. AU - Cowan, A. J. AU - Turtle, C. J. AU - Till, B. G. PY - 2018 DA - 2018// TI - Fully human BCMA targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-117729 DO - 10.1182/blood-2018-99-117729 ID - Green2018 ER - TY - JOUR AU - Cowan, A. J. AU - Pont, M. AU - Sather, B. D. AU - Turtle, C. J. AU - Till, B. G. AU - Nagengast, A. M. PY - 2019 DA - 2019// TI - Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-129405 DO - 10.1182/blood-2019-129405 ID - Cowan2019 ER - TY - JOUR AU - Yan, L. AU - Yan, Z. AU - Shang, J. AU - Shi, X. AU - Jin, S. AU - Kang, L. PY - 2019 DA - 2019// TI - Sequential CD19- and BCMA-specific chimeric antigen receptor T cell treatment for RRMM: report from a single center study JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-129740 DO - 10.1182/blood-2019-129740 ID - Yan2019 ER - TY - JOUR AU - Shi, X. AU - Yan, L. AU - Shang, J. AU - Kang, L. AU - Jin, S. AU - Kang, H. PY - 2019 DA - 2019// TI - Combined infusion of anti-CD19 and anti-BCMA CART cells after early or later transplantation in the front line was superior to salvage therapy for high risk MM JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-131546 DO - 10.1182/blood-2019-131546 ID - Shi2019 ER - TY - JOUR AU - Mikkilineni, L. AU - Manasanch, E. E. AU - Lam, N. AU - Vanasse, D. AU - Brudno, J. N. AU - Maric, I. PY - 2019 DA - 2019// TI - T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-129088 DO - 10.1182/blood-2019-129088 ID - Mikkilineni2019 ER - TY - JOUR AU - Gregory, T. AU - Cohen, A. D. AU - Costello, C. L. AU - Ali, S. A. AU - Berdeja, J. G. AU - Ostertag, E. M. PY - 2018 DA - 2018// TI - Efficacy and safety of p-BCMA-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM) JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-111419 DO - 10.1182/blood-2018-99-111419 ID - Gregory2018 ER - TY - JOUR AU - Han, L. AU - Gao, Q. AU - Zhou, K. AU - Yin, Q. AU - Fang, B. AU - Zhou, J. PY - 2018 DA - 2018// TI - Development and evaluation of CART targeting bcma with humanized alpaca-derived single-domain antibody as antigen recognition domain JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-114980 DO - 10.1182/blood-2018-99-114980 ID - Han2018 ER - TY - JOUR AU - Xu, J. AU - Chen, L. -. J. AU - Yang, S. -. S. AU - Sun, Y. AU - Wu, W. AU - Liu, Y. -. F. PY - 2019 DA - 2019// TI - Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma JO - Proc Natl Acad Sci U S A VL - 116 UR - https://doi.org/10.1073/pnas.1819745116 DO - 10.1073/pnas.1819745116 ID - Xu2019 ER - TY - JOUR AU - Chen, L. AU - Xu, J. AU - Fu, W. AU - Jin, S. AU - Yang, S. AU - Yan, S. PY - 2019 DA - 2019// TI - Updated phase 1 results of a first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA) JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-130008 DO - 10.1182/blood-2019-130008 ID - Chen2019 ER - TY - JOUR AU - Zhao, W. -. H. AU - Liu, J. AU - Wang, B. -. Y. AU - Chen, Y. -. X. AU - Cao, X. -. M. AU - Yang, Y. PY - 2018 DA - 2018// TI - A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0681-6 DO - 10.1186/s13045-018-0681-6 ID - Zhao2018 ER - TY - JOUR AU - Wang, B. -. Y. AU - Zhao, W. -. H. AU - Liu, J. AU - Chen, Y. -. X. AU - Cao, X. -. M. AU - Yang, Y. PY - 2019 DA - 2019// TI - Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed/refractory multiple myeloma (RRMM) JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-124953 DO - 10.1182/blood-2019-124953 ID - Wang2019 ER - TY - JOUR AU - Madduri, D. AU - Usmani, S. Z. AU - Jagannath, S. AU - Singh, I. AU - Zudaire, E. AU - Yeh, T. -. M. PY - 2019 DA - 2019// TI - Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM) JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-121731 DO - 10.1182/blood-2019-121731 ID - Madduri2019 ER - TY - JOUR AU - Hu, Y. AU - Yanlei, Z. AU - Wei, G. AU - Alex Hong, C. AU - Huang, H. PY - 2019 DA - 2019// TI - Potent anti-tumor activity of BCMA CAR-T therapy against heavily treated multiple myeloma and dynamics of immune cell subsets using single-cell mass cytometry JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-130341 DO - 10.1182/blood-2019-130341 ID - Hu2019 ER - TY - JOUR AU - Fu, W. AU - Du, J. AU - Jiang, H. AU - Cheng, Z. AU - Wei, R. AU - Yu, K. PY - 2019 DA - 2019// TI - Efficacy and safety of CAR-T therapy with safety switch targeting bcma for patients with relapsed/refractory multiple myeloma in a phase 1 clinical study JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-127608 DO - 10.1182/blood-2019-127608 ID - Fu2019 ER - TY - JOUR AU - Zhang, H. AU - Gao, L. AU - Liu, L. AU - Wang, J. AU - Wang, S. AU - Gao, L. PY - 2019 DA - 2019// TI - A BCMA and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-131056 DO - 10.1182/blood-2019-131056 ID - Zhang2019 ER - TY - JOUR AU - Cho, S. F. AU - Anderson, K. C. AU - Tai, Y. T. PY - 2018 DA - 2018// TI - Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.01821 DO - 10.3389/fimmu.2018.01821 ID - Cho2018 ER - TY - JOUR AU - Hermanson, D. L. AU - Barnett, B. E. AU - Rengarajan, S. AU - Codde, R. AU - Wang, X. AU - Tan, Y. PY - 2016 DA - 2016// TI - A novel BCMA-specific, centyrin-based CAR-T product for the treatment of multiple myeloma JO - Blood VL - 128 UR - https://doi.org/10.1182/blood.V128.22.2127.2127 DO - 10.1182/blood.V128.22.2127.2127 ID - Hermanson2016 ER - TY - JOUR AU - Zhao, W. -. H. AU - Liu, J. AU - Wang, B. -. Y. AU - Chen, Y. -. X. AU - Cao, X. -. M. AU - Yang, Y. PY - 2018 DA - 2018// TI - Updated analysis of a phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B-cell maturation antigen, in patients with relapsed/refractory multiple myeloma JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-110548 DO - 10.1182/blood-2018-99-110548 ID - Zhao2018 ER - TY - JOUR AU - Shah, N. AU - Chari, A. AU - Scott, E. AU - Mezzi, K. AU - Usmani, S. Z. PY - 2020 DA - 2020// TI - B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches JO - Leukemia VL - 34 UR - https://doi.org/10.1038/s41375-020-0734-z DO - 10.1038/s41375-020-0734-z ID - Shah2020 ER - TY - JOUR AU - Munshi, N. C. AU - Anderson, J. L. D. AU - Shah, N. AU - Jagannath, S. AU - Berdeja, J. G. AU - Lonial, S. PY - 2020 DA - 2020// TI - Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.8503 DO - 10.1200/JCO.2020.38.15_suppl.8503 ID - Munshi2020 ER - TY - JOUR AU - Gust, J. AU - Hay, K. A. AU - Hanafi, L. -. A. AU - Li, D. AU - Myerson, D. AU - Gonzalez-Cuyar, L. F. PY - 2017 DA - 2017// TI - Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-17-0698 DO - 10.1158/2159-8290.CD-17-0698 ID - Gust2017 ER - TY - JOUR AU - Santomasso, B. D. AU - Park, J. H. AU - Salloum, D. AU - Riviere, I. AU - Flynn, J. AU - Mead, E. PY - 2018 DA - 2018// TI - Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-17-1319 DO - 10.1158/2159-8290.CD-17-1319 ID - Santomasso2018 ER - TY - JOUR AU - Fraietta, J. A. AU - Lacey, S. F. AU - Orlando, E. J. AU - Pruteanu-Malinici, I. AU - Gohil, M. AU - Lundh, S. PY - 2018 DA - 2018// TI - Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0010-1 DO - 10.1038/s41591-018-0010-1 ID - Fraietta2018 ER - TY - JOUR AU - Dancy, E. AU - Garfall, A. L. AU - Cohen, A. D. AU - Fraietta, J. A. AU - Davis, M. AU - Levine, B. L. PY - 2018 DA - 2018// TI - Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-115319 DO - 10.1182/blood-2018-99-115319 ID - Dancy2018 ER - TY - JOUR AU - Strohl, W. R. AU - Naso, M. PY - 2019 DA - 2019// TI - Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells JO - Antibodies VL - 8 UR - https://doi.org/10.3390/antib8030041 DO - 10.3390/antib8030041 ID - Strohl2019 ER - TY - JOUR AU - Lam, N. AU - Trinklein, N. D. AU - Buelow, B. AU - Patterson, G. H. AU - Ojha, N. AU - Kochenderfer, J. N. PY - 2020 DA - 2020// TI - Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains JO - Nat Commun VL - 11 UR - https://doi.org/10.1038/s41467-019-14119-9 DO - 10.1038/s41467-019-14119-9 ID - Lam2020 ER - TY - JOUR AU - Ying, Z. AU - He, T. AU - Wang, X. AU - Zheng, W. AU - Lin, N. AU - Tu, M. PY - 2019 DA - 2019// TI - Parallel comparison of 4–1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin's lymphoma JO - Mol Ther Oncolytics VL - 15 UR - https://doi.org/10.1016/j.omto.2019.08.002 DO - 10.1016/j.omto.2019.08.002 ID - Ying2019 ER - TY - JOUR AU - Jagannath, S. AU - Lin, Y. AU - Goldschmidt, H. AU - Reece, D. E. AU - Nooka, A. K. AU - Otero, P. R. PY - 2020 DA - 2020// TI - KarMMa-RW: a study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.8525 DO - 10.1200/JCO.2020.38.15_suppl.8525 ID - Jagannath2020 ER - TY - JOUR AU - Shah, N. AU - Alsina, M. AU - Siegel, D. S. AU - Jagannath, S. AU - Madduri, D. AU - Kaufman, J. L. PY - 2018 DA - 2018// TI - Initial results from a phase 1 clinical study of bb21217, a next-generation anti bcma CAR T therapy JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-116953 DO - 10.1182/blood-2018-99-116953 ID - Shah2018 ER - TY - JOUR AU - Hamieh, M. AU - Dobrin, A. AU - Cabriolu, A. AU - Stegen, S. J. C. AU - Giavridis, T. AU - Mansilla-Soto, J. PY - 2019 DA - 2019// TI - CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape JO - Nature VL - 568 UR - https://doi.org/10.1038/s41586-019-1054-1 DO - 10.1038/s41586-019-1054-1 ID - Hamieh2019 ER - TY - JOUR AU - Berahovich, R. AU - Liu, X. AU - Zhou, H. AU - Tsadik, E. AU - Xu, S. AU - Golubovskaya, V. PY - 2019 DA - 2019// TI - Hypoxia selectively impairs CAR-T cells in vitro JO - Cancers VL - 11 UR - https://doi.org/10.3390/cancers11050602 DO - 10.3390/cancers11050602 ID - Berahovich2019 ER - TY - JOUR AU - Bernabei, L. AU - Garfall, A. L. AU - Melenhorst, J. J. AU - Lacey, S. F. AU - Stadtmauer, E. A. AU - Vogl, D. T. PY - 2018 DA - 2018// TI - PD-1 inhibitor combinations as salvage therapy for relapsed/refractory multiple myeloma (MM) patients progressing after BCMA-directed CAR-T Cells JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-119514 DO - 10.1182/blood-2018-99-119514 ID - Bernabei2018 ER -